Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Fulcrum Therapeutics appoints Judith Dunn as president of R&D » 09:29
03/24/21
03/24
09:29
03/24/21
09:29
FULC

Fulcrum Therapeutics

$11.60 /

-0.4 (-3.33%)

Fulcrum Therapeutics…

Fulcrum Therapeutics announced that Judith Dunn, Ph.D. has been appointed President of Research and Development. Most recently, she supported the development of new companies targeting areas of unmet need in neuroscience as an Entrepreneur in Residence at Atlas Venture.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$11.60 /

-0.4 (-3.33%)

FULC Fulcrum Therapeutics
$11.60 /

-0.4 (-3.33%)

03/22/21 Credit Suisse
Fulcrum Therapeutics initiated with an Outperform at Credit Suisse
03/04/21 Piper Sandler
Fulcrum Therapeutics price target lowered to $20 from $22 at Piper Sandler
03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
FULC Fulcrum Therapeutics
$11.60 /

-0.4 (-3.33%)

  • 20
    Jan
Initiation
Fulcrum Therapeutics initiated with an Outperform at Credit Suisse » 06:18
03/22/21
03/22
06:18
03/22/21
06:18
FULC

Fulcrum Therapeutics

/

+

Credit Suisse analyst…

Credit Suisse analyst Martin Auster initiated coverage of Fulcrum Therapeutics with an Outperform rating and $26 price target. The analyst believes FTX-6058 for sickle cell disease offers a "notable investment opportunity." While the program is just now in a Phase 1 study in healthy volunteers, it should move into patients in 2021 and existing comps highlight the potential for rapid 100%-plus "de-risking" for shares from encouraging data, Auster tells investors in a research note.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
/

+

FULC Fulcrum Therapeutics
/

+

03/04/21 Piper Sandler
Fulcrum Therapeutics price target lowered to $20 from $22 at Piper Sandler
03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
FULC Fulcrum Therapeutics
/

+

  • 20
    Jan
Hot Stocks
Fulcrum Therapeutics announces presentation of new FSHD biomarker data » 11:32
03/18/21
03/18
11:32
03/18/21
11:32
FULC

Fulcrum Therapeutics

$12.63 /

+0.04 (+0.32%)

Fulcrum Therapeutics…

Fulcrum Therapeutics announced the presentation of new data related to the use of imaging biomarkers and clinical outcome assessments for facioscapulohumeral muscular dystrophy, or FSHD, at the 2021 Muscular Dystrophy Association virtual Clinical and Scientific Conference. Presentations included evaluation of disease severity and progression with whole body musculoskeletal magnetic resonance imaging, FSHD-TUG, a modified Timed Up and Go assessment for FSHD patients, and in-home passive measurements of mobility and sleep. Chris Moxham, Ph.D., Fulcrum's chief scientific officer, said, "As we advance our clinical development program for losmapimod for the treatment of FSHD, we are also continually working to improve our ability to assess disease progression based on the most clear and effective outcome measures. Assessments based on musculoskeletal MRI and clinical outcomes may be key to demonstrating patient benefit in this population. We expect full data from our Phase 2b ReDux4 trial late in the second quarter of this year, which will provide additional insights to inform the path forward for losmapimod in the treatment of FSHD."

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$12.63 /

+0.04 (+0.32%)

FULC Fulcrum Therapeutics
$12.63 /

+0.04 (+0.32%)

03/04/21 Piper Sandler
Fulcrum Therapeutics price target lowered to $20 from $22 at Piper Sandler
03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
FULC Fulcrum Therapeutics
$12.63 /

+0.04 (+0.32%)

  • 20
    Jan
Conference/Events
Morgan Stanley to hold a virtual conference » 10:12
03/16/21
03/16
10:12
03/16/21
10:12
ALEC

Alector

$18.70 /

+0.05 (+0.27%)

, AVRO

Avrobio

$13.36 /

+0.34 (+2.61%)

, BOLT

Bolt Biotherapeutics

$39.81 /

+0.99 (+2.55%)

, CABA

Cabaletta Bio

$11.81 /

-0.01 (-0.08%)

, FHTX

Foghorn Therapeutics

$12.71 /

+0.1 (+0.79%)

, FULC

Fulcrum Therapeutics

$11.91 /

-0.06 (-0.50%)

, FUSN

Fusion Pharmaceuticals

$11.70 /

-0.05 (-0.43%)

, HAE

Haemonetics

$118.72 /

-0.44 (-0.37%)

, IMRA

Imara

$10.69 /

-0.08 (-0.74%)

, INSM

Insmed

$36.75 /

+0.15 (+0.41%)

, IVC

Invacare

$8.90 /

+0.13 (+1.48%)

, IRWD

Ironwood

$11.48 /

+0.36 (+3.24%)

, KPTI

Karyopharm

$12.60 /

+0.045 (+0.36%)

, KYMR

Kymera Therapeutics

$59.95 /

-0.335 (-0.56%)

, LEGN

Legend Biotech

$26.15 /

+0.2 (+0.77%)

, PRLD

Prelude Therapeutics

$60.50 /

+1.66 (+2.82%)

, RDUS

Radius Health

$23.11 /

-0.09 (-0.39%)

, RGNX

Regenxbio

$41.78 /

+0.06 (+0.14%)

, RPTX

Repare Therapeutics

$28.50 /

-0.05 (-0.18%)

, SGTX

Sigilon Therapeutics

$26.49 /

+0.36 (+1.38%)

, TNDM

TNDM

/

+

, ZNTL

Zentalis

$44.66 /

-1.09 (-2.38%)

Healthcare Corporate…

Healthcare Corporate Access Virtual Day to be held on March 16.

ShowHide Related Items >><<
ZNTL Zentalis
$44.66 /

-1.09 (-2.38%)

TNDM TNDM
/

+

SGTX Sigilon Therapeutics
$26.49 /

+0.36 (+1.38%)

RGNX Regenxbio
$41.78 /

+0.06 (+0.14%)

RDUS Radius Health
$23.11 /

-0.09 (-0.39%)

PRLD Prelude Therapeutics
$60.50 /

+1.66 (+2.82%)

LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

KYMR Kymera Therapeutics
$59.95 /

-0.335 (-0.56%)

KPTI Karyopharm
$12.60 /

+0.045 (+0.36%)

IVC Invacare
$8.90 /

+0.13 (+1.48%)

IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

INSM Insmed
$36.75 /

+0.15 (+0.41%)

IMRA Imara
$10.69 /

-0.08 (-0.74%)

HAE Haemonetics
$118.72 /

-0.44 (-0.37%)

FUSN Fusion Pharmaceuticals
$11.70 /

-0.05 (-0.43%)

FULC Fulcrum Therapeutics
$11.91 /

-0.06 (-0.50%)

FHTX Foghorn Therapeutics
$12.71 /

+0.1 (+0.79%)

CABA Cabaletta Bio
$11.81 /

-0.01 (-0.08%)

AVRO Avrobio
$13.36 /

+0.34 (+2.61%)

ALEC Alector
$18.70 /

+0.05 (+0.27%)

ALEC Alector
$18.70 /

+0.05 (+0.27%)

01/15/21 BofA
Alector reinstated with a Buy at BofA
11/11/20 Citi
Alector price target lowered to $31 from $40 at Citi
06/24/20 H.C. Wainwright
Alector initiated with a Buy at H.C. Wainwright
04/28/20 Goldman Sachs
Alector initiated with a Buy at Goldman Sachs
AVRO Avrobio
$13.36 /

+0.34 (+2.61%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
BOLT Bolt Biotherapeutics
$39.81 /

+0.99 (+2.55%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
03/02/21 Morgan Stanley
Bolt Biotherapeutics initiated with an Overweight at Morgan Stanley
03/02/21 Stifel
Bolt Biotherapeutics initiated with a Buy at Stifel
CABA Cabaletta Bio
$11.81 /

-0.01 (-0.08%)

01/08/21 Chardan
Cabaletta Bio initiated with a Buy at Chardan
10/13/20 H.C. Wainwright
Cabaletta Bio initiated with a Buy at H.C. Wainwright
FHTX Foghorn Therapeutics
$12.71 /

+0.1 (+0.79%)

11/17/20 Morgan Stanley
Foghorn Therapeutics initiated with an Overweight at Morgan Stanley
11/17/20 Wedbush
Wedbush bullish on Foghorn Therapeutics, initiates with an Outperform
11/17/20 Wedbush
Foghorn Therapeutics initiated with an Outperform at Wedbush
11/17/20 Cowen
Foghorn Therapeutics initiated with an Outperform at Cowen
FULC Fulcrum Therapeutics
$11.91 /

-0.06 (-0.50%)

03/04/21 Piper Sandler
Fulcrum Therapeutics price target lowered to $20 from $22 at Piper Sandler
03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
FUSN Fusion Pharmaceuticals
$11.70 /

-0.05 (-0.43%)

07/21/20
Fly Intel: Top five analyst initiations
07/21/20 Morgan Stanley
Fusion Pharmaceuticals initiated with an Overweight at Morgan Stanley
07/21/20 Wedbush
Wedbush bullish on Fusion Pharmaceuticals, initiates with an Outperform
07/21/20 Jefferies
Fusion Pharmaceuticals initiated with a Buy at Jefferies
HAE Haemonetics
$118.72 /

-0.44 (-0.37%)

02/03/21 Barrington
Haemonetics upgraded to Outperform from Market Perform at Barrington
01/21/21 Barrington
Haemonetics downgraded to Market Perform from Outperform at Barrington
01/21/21 JMP Securities
Haemonetics price target raised to $140 from $110 at JMP Securities
11/05/20 Barrington
Haemonetics upgraded to Outperform from Market Perform at Barrington
IMRA Imara
$10.69 /

-0.08 (-0.74%)

03/08/21 SVB Leerink
Imara price target lowered to $42 from $59 at SVB Leerink
01/06/21 SVB Leerink
Imara selloff a potential buying opportunity, says SVB Leerink
08/17/20
Fly Intel: Top five analyst upgrades
08/17/20 Citi
Imara upgraded to Buy from Neutral at Citi
INSM Insmed
$36.75 /

+0.15 (+0.41%)

02/22/21 Credit Suisse
United Therapeutics price target raised to $196 from $169 at Credit Suisse
01/19/21 Credit Suisse
Insmed price target raised to $60 from $50 at Credit Suisse
12/17/20 Berenberg
Insmed initiated with a Buy at Berenberg
11/23/20 Evercore ISI
Insmed resumed with an Outperform at Evercore ISI
IVC Invacare
$8.90 /

+0.13 (+1.48%)

IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

02/09/21 Gordon Haskett
Ironwood odds of sale improved with CEO exit, says Gordon Haskett
11/06/20 Wells Fargo
Ironwood rally 'looks like a kneejerk overreaction,' says Wells Fargo
09/30/20
Fly Intel: Top five analyst downgrades
09/30/20 Wells Fargo
Ironwood downgraded to Equal Weight at Wells Fargo after pipeline miss
KPTI Karyopharm
$12.60 /

+0.045 (+0.36%)

02/12/21 Barclays
Karyopharm price target lowered to $22 from $26 at Barclays
02/01/21 Barclays
Karyopharm price target lowered to $26 from $31 at Barclays
12/11/20 RBC Capital
Karyopharm's NCCN inclusion should benefit uptake of Xpovio, says RBC Capital
09/25/20 RBC Capital
Karyopharm shares undervalued as seli moves into MF, says RBC Capital
KYMR Kymera Therapeutics
$59.95 /

-0.335 (-0.56%)

03/02/21 Piper Sandler
Kymera Therapeutics plans to file two INDs in 2H21, says Piper Sandler
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
12/04/20 H.C. Wainwright
Kymera Therapeutics initiated with a Buy at H.C. Wainwright
11/24/20 Morgan Stanley
Kymera Therapeutics price target raised to $45 from $27 at Morgan Stanley
LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

07/01/20 JPMorgan
Legend Biotech initiated with an Overweight at JPMorgan
07/01/20 Jefferies
Legend Biotech initiated with a Buy at Jefferies
06/30/20 Morgan Stanley
Legend Biotech initiated with an Overweight at Morgan Stanley
PRLD Prelude Therapeutics
$60.50 /

+1.66 (+2.82%)

11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
11/20/20 BofA
Prelude Therapeutics downgraded to Neutral from Buy at BofA
10/20/20
Fly Intel: Top five analyst initiations
10/20/20 Morgan Stanley
Prelude Therapeutics initiated with an Equal Weight at Morgan Stanley
RDUS Radius Health
$23.11 /

-0.09 (-0.39%)

02/24/21 H.C. Wainwright
Radius Health price target raised to $25 from $22 at H.C. Wainwright
01/07/21 Citi
Radius Health price target raised to $30 from $25 at Citi
10/22/20 H.C. Wainwright
Radius Health price target lowered to $22 from $28 at H.C. Wainwright
09/29/20 JPMorgan
Radius Health resumed with a Neutral at JPMorgan
RGNX Regenxbio
$41.78 /

+0.06 (+0.14%)

02/09/21 Morgan Stanley
Sarepta denied motion to dismiss 'Wilson Wolf' case, says Morgan Stanley
01/20/21 RBC Capital
Regenxbio price target raised to $50 from $42 at RBC Capital
01/06/21 Chardan
Regenxbio named top 2021 pick with $100 target at Chardan
01/06/21 Raymond James
Regenxbio upgraded to Strong Buy from Outperform at Raymond James
RPTX Repare Therapeutics
$28.50 /

-0.05 (-0.18%)

03/01/21 Berenberg
Repare Therapeutics initiated with a Buy at Berenberg
12/29/20 Northland
Northland ups Repare Therapeutics price target to $42, calls a Top Pick for 2021
10/28/20
Fly Intel: Top five analyst initiations
10/28/20 Northland
Repare Therapeutics initiated with an Outperform at Northland
SGTX Sigilon Therapeutics
$26.49 /

+0.36 (+1.38%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
TNDM TNDM
/

+

03/12/21 Piper Sandler
Tandem Diabetes competition concerns overblown, says Piper Sandler
02/25/21 Lake Street
Tandem Diabetes price target raised to $150 from $137 at Lake Street
02/04/21 Piper Sandler
Tandem trades at 'significant discount' to Insulet, says Piper Sandler
01/21/21 Citi
Citi adds Tandem, removes Guardant from 'Value Creators' list
ZNTL Zentalis
$44.66 /

-1.09 (-2.38%)

01/19/21 Wedbush
Zentalis initiated with an Outperform at Wedbush
09/28/20 Cantor Fitzgerald
Cantor starts 'underappreciated' Zentalis with Overweight, $44 target
09/28/20 Cantor Fitzgerald
Zentalis initiated with an Overweight at Cantor Fitzgerald
08/27/20 H.C. Wainwright
Zentalis initiated with a Buy at H.C. Wainwright
ZNTL Zentalis
$44.66 /

-1.09 (-2.38%)

TNDM TNDM
/

+

RPTX Repare Therapeutics
$28.50 /

-0.05 (-0.18%)

RGNX Regenxbio
$41.78 /

+0.06 (+0.14%)

RDUS Radius Health
$23.11 /

-0.09 (-0.39%)

PRLD Prelude Therapeutics
$60.50 /

+1.66 (+2.82%)

LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

KYMR Kymera Therapeutics
$59.95 /

-0.335 (-0.56%)

KPTI Karyopharm
$12.60 /

+0.045 (+0.36%)

IVC Invacare
$8.90 /

+0.13 (+1.48%)

IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

INSM Insmed
$36.75 /

+0.15 (+0.41%)

IMRA Imara
$10.69 /

-0.08 (-0.74%)

HAE Haemonetics
$118.72 /

-0.44 (-0.37%)

FULC Fulcrum Therapeutics
$11.91 /

-0.06 (-0.50%)

FHTX Foghorn Therapeutics
$12.71 /

+0.1 (+0.79%)

CABA Cabaletta Bio
$11.81 /

-0.01 (-0.08%)

AVRO Avrobio
$13.36 /

+0.34 (+2.61%)

ALEC Alector
$18.70 /

+0.05 (+0.27%)

  • 05
    Feb
  • 20
    Jan
  • 08
    Jan
  • 07
    Jan
  • 04
    Dec
  • 20
    Nov
  • 23
    Oct
  • 25
    Sep
  • 21
    Aug
  • 30
    Jul
  • 15
    Jul
  • 26
    Jun
  • 19
    Jun
  • 05
    Jun
  • 05
    May
  • 03
    Apr
IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

SGTX Sigilon Therapeutics
$26.49 /

+0.36 (+1.38%)

RGNX Regenxbio
$41.78 /

+0.06 (+0.14%)

PRLD Prelude Therapeutics
$60.50 /

+1.66 (+2.82%)

LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

KPTI Karyopharm
$12.60 /

+0.045 (+0.36%)

IRWD Ironwood
$11.48 /

+0.36 (+3.24%)

IMRA Imara
$10.69 /

-0.08 (-0.74%)

FHTX Foghorn Therapeutics
$12.71 /

+0.1 (+0.79%)

BOLT Bolt Biotherapeutics
$39.81 /

+0.99 (+2.55%)

AVRO Avrobio
$13.36 /

+0.34 (+2.61%)

LEGN Legend Biotech
$26.15 /

+0.2 (+0.77%)

CABA Cabaletta Bio
$11.81 /

-0.01 (-0.08%)

Over a month ago
Recommendations
Fulcrum Therapeutics price target lowered to $20 from $22 at Piper Sandler » 14:11
03/04/21
03/04
14:11
03/04/21
14:11
FULC

Fulcrum Therapeutics

$12.00 /

-2.59 (-17.75%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff lowered the firm's price target on Fulcrum Therapeutics to $20 from $22 and keeps an Overweight rating on the shares. Fulcrum discontinued the Phase III LOSVID trial of losmapimod due to changes in COVID-19 treatment paradigm. As such, Tenthoff removed losmapimod COVID value from his model. Fulcrum is developing a "rich" preclinical pipeline with the goal of filing two new drug applications in the next 24 months, the analyst tells investors in a research note.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$12.00 /

-2.59 (-17.75%)

FULC Fulcrum Therapeutics
$12.00 /

-2.59 (-17.75%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$12.00 /

-2.59 (-17.75%)

  • 20
    Jan
Hot Stocks
Fulcrum Therapeutics CEO Robert Gould to retire, Bryan Stuart to succeed » 07:23
03/04/21
03/04
07:23
03/04/21
07:23
FULC

Fulcrum Therapeutics

$14.59 /

+0.59 (+4.21%)

Fulcrum Therapeutics…

Fulcrum Therapeutics announced that Bryan Stuart, the company's COO, will become Fulcrum's president and CEO and will be appointed to the Board of Directors. Mr. Stuart will succeed current president and CEO Robert Gould, Ph.D. who will be retiring as of March 31, 2021. Dr. Gould will remain as a member of the Board of Directors and will serve as an advisor to the company. Additionally, Mark Levin, Fulcrum's Board chair, will assume the role of executive chair effective upon Dr. Gould's retirement.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

  • 20
    Jan
Hot Stocks
Fulcrum Therapeutics expects cash to fund requirements into 4Q22 » 07:16
03/04/21
03/04
07:16
03/04/21
07:16
FULC

Fulcrum Therapeutics

$14.59 /

+0.59 (+4.21%)

The company said,…

The company said, "As of December 31, 2020, cash, cash equivalents, and marketable securities were $112.9 million, as compared to $96.7 million as of December 31, 2019. Based on current plans, the company expects that its cash, cash equivalents, and marketable securities as of December 31, 2020, together with the net proceeds of $46.4 million from the sale of its common stock in a public offering on January 22, 2021, will be sufficient to enable Fulcrum to fund operating expenses and capital expenditure requirements into the fourth quarter of 2022."

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

  • 20
    Jan
Hot Stocks
Fulcrum Therapeutics decides to discontinue LOSVID Phase 3 trial » 07:16
03/04/21
03/04
07:16
03/04/21
07:16
FULC

Fulcrum Therapeutics

$14.59 /

+0.59 (+4.21%)

After careful…

After careful consideration, Fulcrum is discontinuing LOSVID, a Phase 3 trial with losmapimod for hospitalized subjects with COVID-19, due to significant changes in the COVID-19 treatment paradigm, including new therapeutic options and emerging vaccines. The company has decided to redeploy its resources to other clinical programs and discovery efforts, with a continued focus on rare diseases. Losmapimod was generally well tolerated in LOSVID, and an independent data safety monitoring board did not identify any safety concerns related to losmapimod.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

  • 20
    Jan
Earnings
Fulcrum Therapeutics reports Q4 EPS (64c), consensus (72c) » 07:15
03/04/21
03/04
07:15
03/04/21
07:15
FULC

Fulcrum Therapeutics

$14.59 /

+0.59 (+4.21%)

Reports Q4 revenue $4.2M,…

Reports Q4 revenue $4.2M, consensus $1.31M. "In 2020, we made meaningful progress in advancing our pipeline despite the extraordinary challenges brought on by COVID-19," said Robert J. Gould, Ph.D., president and chief executive officer. "We have laid the foundation to achieve several key milestones in 2021, including a comprehensive assessment of our Phase 2 ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy late in the second quarter and completing our Phase 1 trial in healthy adult volunteers with FTX-6058, a highly potent small molecule EED inhibitor in development for the treatment of select hemoglobinopathies, including sickle cell disease and beta-thalassemia. Additionally, after careful consideration and a strategic review of the COVID-19 landscape, we are discontinuing our LOSVID trial. This enables us to focus on rare diseases. I would like to thank the patients and investigators who participated in this trial and the Fulcrum team who worked tirelessly to rapidly design and launch the LOSVID trial during a global pandemic. Furthermore, we have made great progress with our next-generation product engine including new levels of validation in our internal research efforts and externally through our strategic collaborations," continued Dr. Gould. "With the additional capital from our recent public offering, we have extended our cash runway into the fourth quarter of 2022 and we believe that we are well positioned to continue progress on our goal to advance therapies to improve the lives of patients with genetically defined rare diseases."

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

03/01/21 Stifel
Fulcrum Therapeutics initiated with a Buy at Stifel
10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
FULC Fulcrum Therapeutics
$14.59 /

+0.59 (+4.21%)

  • 20
    Jan
Initiation
Fulcrum Therapeutics initiated with a Buy at Stifel » 16:37
03/01/21
03/01
16:37
03/01/21
16:37
FULC

Fulcrum Therapeutics

$12.92 /

+0.37 (+2.95%)

Stifel analyst Dae Gon Ha…

Stifel analyst Dae Gon Ha initiated coverage of Fulcrum Therapeutics with a Buy rating and $18 price target. To say 2021 "marks an important year" for Fulcrum "is an understatement," said Ha, who notes that Phase 2b ReDUX4 data are expected in Q2. The "the comprehensive nature of the readout, and its implications on losmapimod and the facioscapulohumeral muscular dystrophy program," should be expected to create volatility, said Ha, who assigns 40% probability of success to reflect his view ahead of this readout. However, Ha also believes another asset, FTX-6058, "may be emerging as an attractive thesis for investors."

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$12.92 /

+0.37 (+2.95%)

FULC Fulcrum Therapeutics
$12.92 /

+0.37 (+2.95%)

10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
08/12/20 Morgan Stanley
Fulcrum Therapeutics downgraded at Morgan Stanley, price target slashed to $11
FULC Fulcrum Therapeutics
$12.92 /

+0.37 (+2.95%)

  • 20
    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.